Gilead/Bristol Hep C Combo Gets High Marks At EASL, But Its Future Is In Doubt

23 Apr 2012

• By Shirley Haley

All eyes are on Gilead Sciences following the news it may not continue development of GS-7977 alongside Bristol-Myers Squibb’s daclatasvir, though the all-oral pairing produced impressive data in Phase II.

Gilead Sciences Inc. is on the hot seat as the hepatitis C community waits for signs of what compounds the company might pair with its nucleotide polymerase inhibitor GS-7977 in Phase III, following the release of smashing Phase II combination data released at the International Liver Congress in Barcelona April 19.

An all-oral combination of ‘7977 and Bristol-Myers Squibb Co.’s NS5A replication complex inhibitor daclatasvir created a sustained viral response...